Ascorbic Acid (Monograph)
Brand name: Ascor
Drug class: Vitamin C
ATC class: A11GA01
VA class: VT400
Chemical name: l-ascorbic acid
CAS number: 50-81-7
Introduction
An essential water-soluble vitamin; ascorbic acid is the in vivo form of vitamin C.109
Uses for Ascorbic Acid
Scurvy
Prevention and treatment of scurvy.a
Dietary Requirements
Adequate intake needed to prevent scurvy and provide antioxidant protection.109
Adequate vitamin C intake can be accomplished through consumption of foodstuffs.109 Citrus fruits, tomatoes, and potatoes are the major contributors of vitamin C in the diet of US adults and children.109
Recommended Dietary Allowances (RDA) in adults based on near maximal neutrophil concentrations with minimal urinary excretion of ascorbate.109
Requirements slightly lower in women than men based on water-soluble nature of the vitamin and the larger lean body mass and total body water in males relative to females.109
Adequate intake (AI) established for infants ≤6 months of age based on observed mean vitamin C intake of infants fed principally human milk; AI for infants 7–12 months of age based on vitamin C intake from human milk and solid food.109
RDA for children 1–18 years of age based on data in adults.109
Macular Degeneration
Suggested as a component of high-dose antioxidant supplements with zinc to reduce risk of developing advanced age-related macular degeneration† [off-label] in high-risk patients (i.e., those with intermediate stage age-related macular degeneration or advanced stage macular degeneration in only one eye).111 112
Respiratory Infections
Large doses have been advocated for lessening severity of and for preventing the common cold† [off-label].a Routine supplementation modestly decreases duration of symptoms; also appears to decrease incidence in individuals under heavy physical stress but not in the overall population.202 203 211 No consistent effect on duration or severity of symptoms when initiated following symptom onset.202 211
Limited study data available regarding effects in the prevention or treatment of pneumonia† [off-label]; available studies were conducted under specific circumstances and may not be applicable to the general population.202 203
Studies required to establish efficacy of adjunctive ascorbic acid therapy in the treatment of severe viral respiratory infections† [off-label].206
Sepsis
High-dose IV ascorbic acid has been evaluated in patients with sepsis† [off-label];204 208 209 210 efficacy remains to be established.209 210 212 213
Meta-analysis of several small studies suggested beneficial effects from adjunctive IV ascorbic acid in patients with sepsis, but primary efficacy end points were not improved in 2 subsequent multicenter, randomized studies (CITRIS-ALI, VITAMINS).208 209 210 Additional studies under way.204 213
Methemoglobinemia
Has been used in the treatment of idiopathic methemoglobinemia†.a
Related/similar drugs
acetylcysteine, biotin, multivitamin, Vitamin C, Dextrose, niacin, Phospha 250 Neutral
Ascorbic Acid Dosage and Administration
Administration
Usually administered orally.a May be administered by IM, IV, or sub-Q injection when oral administration is not feasible or when malabsorption is suspected.a
Parenteral Administration
Preferred parenteral method of administration is IM.a
Pressure may build within the vial during storage.b Exercise care when withdrawing a dose and/or insert a vent needle (e.g., empty sterile syringe) into the vial to release the pressure.b
IV Administration
Dilution
For solution and drug compatibility, see Compatibility under Stability.
Dilute with large volume of compatible parenteral fluid to minimize adverse reactions.b Avoid rapid infusion.b
Dosage
Available as ascorbic acid, calcium ascorbate, and sodium ascorbate; dosage expressed in terms of ascorbic acid.b d
Pediatric Patients
Scurvy
Treatment
Oral or IV100–300 mg daily for 1 month or until full recovery.a c
Dietary and Replacement Requirements
Oral
Infants ≤6 months of age: Recommended AI is 40 mg (about 6 mg/kg) daily.109
Infants 7–12 months of age: Recommended AI is 50 mg (about 6 mg/kg) daily.109
Children 1–3 years of age: RDA is 15 mg daily.109
Children 4–8 years of age: RDA is 25 mg daily.109
Children 9–13 years of age: RDA is 45 mg daily.109
Boys 14–18 years of age: RDA is 75 mg daily.109
Girls 14–18 years of age: RDA is 65 mg daily.109
Adults
Scurvy
Treatment
Oral or IV300 mg–1 g daily for 1 month or until full recovery.b c
Dietary and Replacement Requirements
Oral
Men ≥19 years of age: RDA is 90 mg daily.109
Women ≥19 years of age: RDA is 75 mg daily.109
Macular Degeneration†
Oral
500 mg in combination with beta carotene 15 mg, vitamin E 400 units, and zinc (as zinc oxide) 80 mg, with copper (as cupric oxide) 2 mg (to prevent anemia) daily has been used.111 112
Respiratory Infections†
Common Cold†
Oral1–3 g or greater per day has been recommended for prevention and treatment.a
Idiopathic Methemoglobinemia†
Oral
300–600 mg daily in divided doses has been used.a
Special Populations
Pregnant Women
RDA for pregnant women 14–18 years of age is 80 mg daily.109
RDA for pregnant women 19–50 years of age is 85 mg daily.109
Requirements increased in pregnant women to ensure transfer of adequate amounts of the vitamin to the fetus.109
Lactating Women
RDA for lactating women 14–18 or 19–50 years of age is 115 or 120 mg daily, respectively.109
Requirements increased in lactating women to ensure adequate concentration of the vitamin in milk.109
Smokers
RDA increased by 35 mg daily.109
Smoking increases oxidative stress and metabolic turnover of vitamin C.109
Cautions for Ascorbic Acid
Contraindications
-
Manufacturer states no known contraindications.b
Warnings/Precautions
General Precautions
Sodium Content
Each 1 gram of sodium ascorbate contains approximately 5 mEq of sodium; consider sodium content in patients on sodium-restricted diets.a
Kidney Stone Formation
Kidney stone (renal calculus) formation reported in individuals with renal disease receiving large dosages of ascorbic acid; excess ascorbic acid intake not associated with kidney stone formation in healthy individuals.109
Aluminum Content
Some ascorbic acid injection preparations contain aluminum that may be toxic.b Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired.b Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.b
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum >4–5 mcg/kg daily accumulate aluminum at levels associated with CNS and bone toxicity.b Tissue loading may occur at even lower rates of administration.b
Specific Populations
Pregnancy
Category C.b
Lactation
Distributed into milk.a Caution if parenteral preparation is used in nursing women.b
Common Adverse Effects
Relatively nontoxic; nausea, vomiting, heartburn, fatigue, flushing, headache, insomnia, sleepiness, and other GI disturbances (diarrhea, transient colic, abdominal cramps, flatulent distention) reported.a
Drug Interactions
Laboratory Tests
Interferes with numerous laboratory tests based on oxidation-reduction reactions.a Degree of interference depends on several factors (e.g., ascorbic acid concentration, resulting pH, specific reagents).a Consult specialized references.a
Specific Drugs and Laboratory Tests
Drug or Test |
Interaction |
Comments |
---|---|---|
Aspirin |
Increased urinary excretion of ascorbic acid and decreased excretion of aspirin reported with concomitant administrationa |
|
Fluphenazine |
Decreased fluphenazine concentrationsa |
|
Iron, oral |
Increased GI absorption of irona |
|
Tests for detection of occult blood in stool |
Possible false-negative resultsb |
Manufacturer of parenteral ascorbic acid recommends discontinuing vitamin C supplements 48–72 hours before testb |
Tests for glucose in urine |
Possible false-positive with tests based on cupric sulfate reagent and false-negative with tests that use glucose oxidase methoda |
|
Warfarin |
Decreased anticoagulant effect reported; other investigators did not observe this effecta |
Ascorbic Acid Pharmacokinetics
Absorption
Bioavailability
Readily absorbed by an active process that may be limited after very large doses.a
Distribution
Extent
Widely distributed in body tissues.a
Crosses the placenta; cord blood concentration 2–4 times maternal blood concentrations.a Distributed into human milk.a
Plasma Protein Binding
About 25%.a
Elimination
Metabolism
Reversibly oxidized to dehydroascorbic acid.a
Elimination Route
Excreted in urine. a
Removed by hemodialysis.a
Stability
Storage
Oral
Capsules and Tablets
Cool dry place.d
Parenteral
Solution
Store in carton until time of use at room temperature (≤25°C).b Protect from light. b
Compatibility
Parenteral
Solution CompatibilityHID
Compatible |
---|
Dextran 6% in dextrose 5% |
Dextran 6% in sodium chloride 0.9% |
Dextrose-Ringer’s injection combinations |
Dextrose-Ringer’s injection, lactated, combinations |
Dextrose-saline combinations |
Dextrose 2½, 5, or 10% in water |
Fructose 10% in sodium chloride 0.9% |
Fructose 10% in water |
Invert sugar 5 and 10% in sodium chloride 0.9% |
Invert sugar 5 and 10% in water |
Ionosol products |
Ringer’s injection |
Ringer’s injection, lactated |
Sodium chloride 0.45 or 0.9% |
Sodium lactate (1/6) M |
Variable |
Fat emulsion 10%, IV |
Drug Compatibility
Compatible |
---|
Amikacin sulfate |
Calcium chloride |
Calcium gluconate |
Chloramphenicol sodium succinate |
Chlorpromazine HCl |
Colistimethate sodium |
Cyanocobalamin |
Dimenhydrinate HCl |
Heparin sodium |
Kanamycin sulfate |
Methyldopate HCl |
Penicillin G potassium |
Polymyxin B sulfate |
Procaine HCl |
Prochlorperazine edisylate |
Promethazine HCl |
Verapamil HCl |
Incompatible |
Bleomycin sulfate |
Nafcillin sodium |
Sodium bicarbonate |
Theophylline |
Variable |
Aminophylline |
Erythromycin lactobionate |
Compatible |
---|
Warfarin sodium |
Incompatible |
Etomidate |
Thiopental sodium |
Actions
-
An essential water-soluble vitamin present in fresh fruits and vegetables.a Vitamin C refers to both ascorbic acid and dehydroascorbic acid (DHA); both compounds exhibit antiscorbutic activity.109
-
An antioxidant and a cofactor in enzymatic and metabolic processes.109
-
Required for collagen formation and tissue repair.b
Advice to Patients
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.a
-
Importance of proper dietary habits, including taking appropriate AI or RDA of vitamin C.a
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a
-
Importance of informing patients of other important precautionary information.a (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Bulk |
Powder* |
|||
Parenteral |
Injection |
500 mg/mL* |
Ascor |
McGuff |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Bulk |
Powder* |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 13, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
73. Nienhuis A, Delea C, Aamodt R et al. Potential role for desferrioxamine and ascorbic acid in the treatment of chronic iron overload. Blood. 1975. 46:1026. Abstract. (IDIS 64329)
74. Hussain MAM, Flynn DM, Green N et al. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet. 1977; 1:977-9. http://www.ncbi.nlm.nih.gov/pubmed/67469?dopt=AbstractPlus
75. Modell B. Total management of thalassemia major. Arch Dis Child. 1977; 52:489-500. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1544709&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/879834?dopt=AbstractPlus
100. Wolfe L, Olivieri N, Sallan D et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985; 312:1600-3. http://www.ncbi.nlm.nih.gov/pubmed/4000198?dopt=AbstractPlus
101. Marcus RE, Davies SC, Bantock HM et al. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet. 1984; 1:392-3. http://www.ncbi.nlm.nih.gov/pubmed/6141447?dopt=AbstractPlus
102. Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high-dose subcutaneous desferrioxamine. Lancet. 1984; 1:681. http://www.ncbi.nlm.nih.gov/pubmed/6142370?dopt=AbstractPlus
103. Olivieri NF, Buncic R, Chew E et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986; 314:869-73. http://www.ncbi.nlm.nih.gov/pubmed/3485251?dopt=AbstractPlus
104. Nienhuis AW, Benz EJ, Propper R et al. Thalassemia major: molecular and clinical aspects. Ann Intern Med. 1979; 91:883-97. http://www.ncbi.nlm.nih.gov/pubmed/391118?dopt=AbstractPlus
105. Nienhuis AW. Vitamin C and iron. N Engl J Med. 1981; 304:170-1. http://www.ncbi.nlm.nih.gov/pubmed/7442737?dopt=AbstractPlus
106. Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood. 1982; 60:288-94. http://www.ncbi.nlm.nih.gov/pubmed/7093519?dopt=AbstractPlus
107. Modell B, Petrou M. Management of thalassaemia major. Arch Dis Child. 1983; 58:1026-30. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1628578&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6660889?dopt=AbstractPlus
108. National Research Council Food and Nutrition Board Subcommittee on the Tenth Edition of the RDAs. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press; 1989:115-24.
109. Committee on the Scientific Evaluation of Dietary Reference Intakes of the Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. Dietary reference intakes for Vitamin C, Vitamin E, selenium, and carotenoids. Washington, DC: National Academy Press; 2000.
110. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes of the Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997. (Uncorrected proofs.)
111. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol. 2001; 119:1417-36. http://www.ncbi.nlm.nih.gov/pubmed/11594942?dopt=AbstractPlus
112. Jampol LM. Antioxidants, zinc, and age-related macular degeneration. Arch Ophthalmol. 2001;119:1533-4. Editorial.
202. Hemilä H. Vitamin C and Infections. Nutrients. 2017; 9 http://www.ncbi.nlm.nih.gov/pubmed/28353648?dopt=AbstractPlus
203. Hemilä H, Louhiala P. Vitamin C for preventing and treating pneumonia. Cochrane Database Syst Rev. 2013; :CD005532. http://www.ncbi.nlm.nih.gov/pubmed/23925826?dopt=AbstractPlus
204. Kashiouris MG, L'Heureux M, Cable CA et al. The Emerging Role of Vitamin C as a Treatment for Sepsis. Nutrients. 2020; 12 http://www.ncbi.nlm.nih.gov/pubmed/31978969?dopt=AbstractPlus
205. Marik PE. Vitamin C: an essential “stress hormone” during sepsis. J Thorac Dis. 2020; 12:S84-S88. http://www.ncbi.nlm.nih.gov/pubmed/32148930?dopt=AbstractPlus
206. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020; 46:315-328. http://www.ncbi.nlm.nih.gov/pubmed/32040667?dopt=AbstractPlus
208. Li J. Evidence is stronger than you think: a meta-analysis of vitamin C use in patients with sepsis. Crit Care. 2018; 22:258. http://www.ncbi.nlm.nih.gov/pubmed/30305111?dopt=AbstractPlus
209. Fowler AA, Truwit JD, Hite RD et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019; 322:1261-1270. http://www.ncbi.nlm.nih.gov/pubmed/31573637?dopt=AbstractPlus
210. Fujii T, Luethi N, Young PJ et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial. JAMA. 2020; http://www.ncbi.nlm.nih.gov/pubmed/31950979?dopt=AbstractPlus
211. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013; :CD000980. http://www.ncbi.nlm.nih.gov/pubmed/23440782?dopt=AbstractPlus
212. Brant EB, Angus DC. Is High-Dose Vitamin C Beneficial for Patients With Sepsis?. JAMA. 2019; 322:1257-1258. http://www.ncbi.nlm.nih.gov/pubmed/31573621?dopt=AbstractPlus
213. Kalil AC. Lack of Benefit of High-Dose Vitamin C, Thiamine, and Hydrocortisone Combination for Patients With Sepsis. JAMA. 2020; http://www.ncbi.nlm.nih.gov/pubmed/31950983?dopt=AbstractPlus
a. AHFS drug information 2020. Snow EK, ed. Ascorbic Acid. Bethesda, MD: American Society of Health-Systems Pharmacists; .
b. Luitpold Pharmaceuticals, Inc. Ascorbic Acid Injection prescribing information. Shirley, NY; 2000 Jun.
c. Weinstein, M, Babyn P, Zlotkin S. An orange a day keeps the doctor away: scurvy in the year 2000. Pediatrics. 2001; 108:e55.
d. GNC A-Z vitamin C 500 mg tablets package information. Accessed 24 May 2007. http://www.drugstore.com
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:171-6.
More about ascorbic acid
- Check interactions
- Compare alternatives
- Reviews (7)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: vitamins
- Breastfeeding